$0.27 EPS Expected for Merit Medical Systems, Inc. (NASDAQ:MMSI) This Quarter

Equities analysts expect that Merit Medical Systems, Inc. (NASDAQ:MMSI) will post earnings of $0.27 per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Merit Medical Systems’ earnings, with the highest EPS estimate coming in at $0.35 and the lowest estimate coming in at $0.20. Merit Medical Systems reported earnings per share of $0.37 in the same quarter last year, which would suggest a negative year over year growth rate of 27%. The firm is scheduled to issue its next earnings report on Tuesday, April 28th.

According to Zacks, analysts expect that Merit Medical Systems will report full-year earnings of $1.56 per share for the current fiscal year, with EPS estimates ranging from $1.52 to $1.62. For the next year, analysts anticipate that the company will report earnings of $1.72 per share, with EPS estimates ranging from $1.50 to $1.85. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Merit Medical Systems.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Monday, February 24th. The medical instruments supplier reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $257.92 million during the quarter, compared to the consensus estimate of $252.31 million. Merit Medical Systems had a net margin of 0.55% and a return on equity of 8.67%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 earnings per share.

MMSI has been the subject of several recent analyst reports. Wells Fargo & Co upped their price objective on shares of Merit Medical Systems from $26.00 to $33.00 and gave the company an “underweight” rating in a research note on Tuesday, February 25th. Oppenheimer upped their price objective on shares of Merit Medical Systems from to in a research note on Friday, February 7th. Raymond James upped their price objective on shares of Merit Medical Systems from $43.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, February 25th. ValuEngine raised shares of Merit Medical Systems from a “hold” rating to a “buy” rating in a research note on Saturday, February 1st. Finally, Barrington Research downgraded shares of Merit Medical Systems from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $44.50.

Merit Medical Systems stock traded down $0.02 during mid-day trading on Monday, hitting $32.98. The company’s stock had a trading volume of 479,393 shares, compared to its average volume of 703,085. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.50 and a quick ratio of 1.26. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of 366.49, a price-to-earnings-growth ratio of 1.75 and a beta of 0.85. The business has a 50 day moving average price of $36.26 and a 200-day moving average price of $31.92. Merit Medical Systems has a 12 month low of $19.50 and a 12 month high of $63.64.

In related news, Director A Scott Anderson sold 6,638 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $37.29, for a total transaction of $247,531.02. Following the transaction, the director now owns 11,400 shares in the company, valued at $425,106. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Franklin J. Miller sold 15,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $38.07, for a total transaction of $571,050.00. Following the transaction, the director now owns 17,334 shares in the company, valued at approximately $659,905.38. The disclosure for this sale can be found here. Insiders have sold 23,969 shares of company stock worth $900,749 in the last quarter. 4.75% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC increased its position in shares of Merit Medical Systems by 1,878.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,088 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 1,033 shares during the period. Macquarie Group Ltd. increased its position in shares of Merit Medical Systems by 6.8% during the fourth quarter. Macquarie Group Ltd. now owns 1,682,643 shares of the medical instruments supplier’s stock valued at $52,532,000 after buying an additional 107,515 shares during the period. Nuveen Asset Management LLC grew its holdings in Merit Medical Systems by 17.6% in the fourth quarter. Nuveen Asset Management LLC now owns 843,000 shares of the medical instruments supplier’s stock worth $26,319,000 after purchasing an additional 126,168 shares during the period. Norges Bank purchased a new stake in Merit Medical Systems in the fourth quarter worth about $19,125,000. Finally, CA Family Wealth LLC purchased a new stake in Merit Medical Systems in the fourth quarter worth about $251,000. Institutional investors own 97.48% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions.

Recommended Story: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Merit Medical Systems (MMSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merit Medical Systems (NASDAQ:MMSI)

Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.